文献速递血栓与止血

人Fcγ受体IIIA阻断在ITP人源化小鼠模型中抑制血小板破坏

Human Fc gamma receptor IIIA blockade inhibits platelet destruction in a humanized murine model of ITP.
PubMed 文献 · Blood Adv · 2024-01-01

研究开发了高亲和力单价单链可变片段(scFv)17C02,以白蛋白融合蛋白、单臂人IgG1抗体和标准双价小鼠IgG2a抗体三种形式表达。两种单价形式均能阻止ITP血清致敏人血小板的吞噬,并在FcγR人源化小鼠体内增加血小板计数;白蛋白融合蛋白未引起体温变化,而单臂抗体虽Fc功能因Leu234Ala和Leu235Ala突变受损仍引起部分体温变化。

要点

  • 单价scFv 17C02的两种单价形式均可阻止ITP血清致敏人血小板的吞噬。
  • 在FcγR人源化小鼠体内,两种单价治疗均能增加血小板计数。
  • 白蛋白融合蛋白未引起体温变化,单臂抗体引起部分体温变化。

核心结论

  • 体内单价阻断人FcγRIIIA可能成为ITP患者的治疗策略。

研究设计与样本

  • 开发高亲和力单价单链可变片段(scFv)17C02,并以白蛋白融合蛋白、单臂人IgG1抗体和标准双价小鼠IgG2a抗体三种形式表达,在体外吞噬实验和FcγR人源化小鼠体内进行研究。

主要发现

  • 两种单价形式均能有效阻止ITP血清致敏人血小板的吞噬。
  • FcγR人源化小鼠体内研究显示两种单价治疗均能增加血小板计数。
  • 白蛋白融合蛋白未引起体温变化,单臂抗体虽Fc区域功能因Leu234Ala和Leu235Ala突变受损仍引起部分体温变化。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fc gamma receptor (FcγR) IIIA is an important receptor for immunoglobulin G (IgG) and is involved in immune defense mechanisms as well as tissue destruction in some autoimmune diseases including immune thrombocytopenia (ITP). FcγRIIIA on macrophages can trigger phagocytosis of IgG-sensitized platelets, and prior pilot studies observed blockade of FcγRIIIA increased platelet counts in patients with ITP. Unfortunately, although blockade of FcγRIIIA in patients with ITP increased platelet counts, its engagement by the blocking antibody drove serious adverse inflammatory reactions. These adverse events were postulated to originate from the antibody's Fc and/or bivalent nature. The blockade of human FcγRIIIA in vivo with a monovalent construct lacking an active Fc region has not yet been achieved. To effectively block FcγRIIIA in vivo, we developed a high affinity monovalent single-chain variable fragment (scFv) that can bind and block human FcγRIIIA. This scFv (17C02) was expressed in 3 formats: a monovalent fusion protein with albumin, a 1-armed human IgG1 antibody, and a standard bivalent mouse (IgG2a) antibody. Both monovalent formats were effective in preventing phagocytosis of ITP serum-sensitized human platelets. In vivo studies using FcγR-humanized mice demonstrated that both monovalent therapeutics were also able to increase platelet counts. The monovalent albumin fusion protein did not have adverse event activity as assessed by changes in body temperature, whereas the 1-armed antibody induced some changes in body temperature even though the Fc region function was impaired by the Leu234Ala and Leu235Ala mutations. These data demonstrate that monovalent blockade of human FcγRIIIA in vivo can potentially be a therapeutic strategy for patients with ITP.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Gil Gonzalez L, Won KD, Tawhidi Z, et al. Human Fc gamma receptor IIIA blockade inhibits platelet destruction in a humanized murine model of ITP. Blood Adv. 2024. PMID: 38330193. doi:10.1182/bloodadvances.2023012155

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。